Drug Shortage Report for RIVASTIGMINE
| Report ID | 236658 |
| Drug Identification Number | 02417014 |
| Brand name | RIVASTIGMINE |
| Common or Proper name | RIVASTIGMINE |
| Company Name | PRO DOC LIMITEE |
| Market Status | MARKETED |
| Active Ingredient(s) | RIVASTIGMINE |
| Strength(s) | 4.5MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
|
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
| Additional packaging sizes | 100 |
| ATC code | N06DA |
| ATC description | ANTI-DEMENTIA DRUGS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | 2024-10-07 |
| Actual start date | 2024-10-09 |
| Estimated end date | Unknown |
| Actual end date | 2025-04-04 |
| Shortage status | Resolved |
| Updated date | 2025-04-05 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2925 BOULEVARD INDUSTRIEL LAVAL, QUEBEC CANADA H7L 3W9 |
| Company contact information | 2925 BOULEVARD INDUSTRIEL, LAVAL QC, H7L 3W9 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2024-09-04 | English | Compare |